ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Dimethyl sulfoxide: Drug information

Dimethyl sulfoxide: Drug information
(For additional information see "Dimethyl sulfoxide: Patient drug information" and see "Dimethyl sulfoxide: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Rimso-50
Brand Names: Canada
  • Rimso-50
Pharmacologic Category
  • Antidote, Extravasation;
  • Urinary Tract Product
Dosing: Adult
Extravasation management

Extravasation management (anthracyclines, mitomycin, or mitoxantrone; off-label use): Topical dimethyl sulfoxide: Apply to a region covering twice the affected area every 8 hours for 7 days. Begin within 10 minutes of extravasation; do not cover with a dressing (Ref).

Interstitial cystitis

Interstitial cystitis: Bladder instillation: Instill 50 mL directly into bladder and retain for 15 minutes; repeat every 2 weeks until symptoms are relieved, then increase intervals between treatments or 50 mL directly into bladder and retain for 15 to 20 minutes every 1 to 2 weeks for 4 to 8 treatments (Ref).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Dimethyl sulfoxide: Pediatric drug information")

Extravasation management, anthracyclines or mitomycin

Extravasation management, anthracyclines or mitomycin: Limited data available: Children and Adolescents: Topical dimethyl sulfoxide: Apply to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (Ref).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.

Dermatologic: Body odor (garlic; duration: Up to 72 hours)

Gastrointestinal: Halitosis/unpleasant taste (garlic; onset: Within a few minutes after instillation; duration: Up to 72 hours)

Genitourinary: Bladder pain, cystitis (transient)

Local: Localized erythema (topical application; ESMO/EONS [Pérez Fidalgo 2012])

Hypersensitivity: Hypersensitivity

Postmarketing and/or case reports: Contact dermatitis, cystitis (eosinophilic), pigment deposits on lens

Contraindications

There are no contraindications listed in the manufacturer's labeling.

Warnings/Precautions

Concerns related to adverse effects:

• Bladder symptoms: Bladder discomfort may occur; generally diminishes with repeated administration.

• Hypersensitivity reactions: Hypersensitivity reactions have been reported with intravesical administration (rare); hypersensitivity has also occurred with topical administration. If anaphylactoid symptoms occur, manage appropriately.

• Ophthalmic effects: Lens changes and opacities have been observed in animal studies. Full eye exams (including slit lamp) are recommended prior to use and periodically during treatment.

• Taste alteration: A garlic-like taste may occur, beginning a few minutes after instillation and lasting for several hours. Garlic odor on the breath and skin may also occur and persist for up to 3 days.

Disease-related concerns:

• Urinary tract malignancy: Use with caution in patients with urinary tract malignancy; may be harmful due to vasodilatory effects.

Other warnings/precautions:

• Appropriate use: For bladder instillation or topical administration for extravasation management (off-label use) only; not for IV or IM administration. Do not use in patients receiving dexrazoxane for anthracycline extravasation (Mourdisen, 2007); dimethyl sulfoxide (DMSO) may diminish dexrazoxane efficacy.

Warnings: Additional Pediatric Considerations

Severe pain following topical administration of dimethyl sulfoxide (DMSO) has been reported in a 4-year-old patient who was receiving DMSO for idarubicin extravasation; administration of analgesia (nonopioid or opioid) prior to DMSO application did not provide effective pain control; DMSO treatment was discontinued after 5 days due to pain with application and significant erythema; after discontinuation, no further analgesia was required (Llinares 2005).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravesical:

Rimso-50: 50% (50 mL)

Generic Equivalent Available: US

No

Pricing: US

Solution (Rimso-50 Intravesical)

50% (per mL): $15.89

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravesical:

Rimso-50: 50% (50 mL)

Administration: Adult

Intravesical (for interstitial cystitis): Instill directly into the bladder via catheter or syringe. To reduce bladder spasm, apply an analgesic lubricant (eg, lidocaine jelly) to urethra prior to catheter insertion; oral analgesics or belladonna and opium suppositories prior to administration may be of benefit. Not for IV or IM use.

Extravasation management (off-label use): Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do NOT flush the line); remove needle/cannula; elevate extremity. Apply dimethyl sulfoxide topically (within 10 minutes of extravasation) to extravasation site, covering an area twice the size of extravasation; allow to air dry; do not cover with a dressing (Ref).

Administration: Pediatric

Not for IV or IM use.

Topical: Extravasation management, anthracyclines or mitomycin: Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do NOT flush the line); remove needle/cannula; elevate extremity. Apply dimethyl sulfoxide topically (within 10 minutes of extravasation) to extravasation site, covering an area twice the size of extravasation; allow to air dry; do not cover with a dressing (Ref).

Use: Labeled Indications

Interstitial cystitis: Symptomatic relief of interstitial cystitis.

Limitation of use: There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial urinary tract infections.

Use: Off-Label: Adult

Extravasation management

Medication Safety Issues
Sound-alike/look-alike issues:

Dimethyl sulfoxide may be confused with dimethyl fumarate

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Dexrazoxane: Dimethyl Sulfoxide may diminish the therapeutic effect of Dexrazoxane. Risk X: Avoid combination

Sulindac: Dimethyl Sulfoxide may enhance the neurotoxic effect of Sulindac. Dimethyl Sulfoxide may decrease the metabolism of Sulindac. Specifically, the concentrations of the active sulfide metabolite are decreased. Risk C: Monitor therapy

Pregnancy Considerations

Adverse events have been observed in some animal reproduction studies.

Breastfeeding Considerations

It is not known if dimethyl sulfoxide is excreted in breast milk. The manufacturer recommends that caution be exercised when administering dimethyl sulfoxide to nursing women.

Monitoring Parameters

CBC, chemistry panel, liver and renal function tests about every 6 months; eye examinations and slit lamp examinations (baseline and periodically during treatment). For extravasation management, monitor and document extravasation site.

Mechanism of Action

For management of cystitis, dimethyl sulfoxide (DMSO) has anti-inflammatory, analgesic, mast cell inhibition, and muscle relaxing effects (Chancellor, 2004). DMSO also has free-radical scavenger properties, which increases removal of vesicant drugs from tissues to minimize tissue damage in extravasation management (ESMO/EONS [Pérez Fidalgo 2012]).

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Topical: Well absorbed from application site

Distribution: Topical: Rapidly penetrates tissues (Bertelli 1995)

Metabolism: Oxidation to dimethyl sulfone; reduction to dimethyl sulfide

Excretion: Urine and feces (as unchanged drug and dimethyl sulfone); some elimination via skin and lungs (dimethyl sulfide)

  1. Albanell J and Baselga J, “Systemic Therapy Emergencies,” Semin Oncol, 2000, 27(3):347-61. [PubMed 10864222]
  2. Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Saf. 1995;12(4):245-255. [PubMed 7646823]
  3. Chancellor MB and Yoshimura N, “Treatment of Interstitial Cystitis,” Urology, 2004, 63(Suppl 1):85-92. [PubMed 15013658]
  4. Ener RA, Meglathery SB, and Styler M, "Extravasation of Systemic Hemato-oncological Therapies," Ann Oncol, 2004, 15(6):858-62. [PubMed 15151940]
  5. Llinares ME, Bermúdez M, Fuster JL, Diaz MS, Gonzalez CM. Toxicity to topical dimethyl sulfoxide in a pediatric patient with anthracycline extravasation. Pediatr Hematol Oncol. 2005;22(1):49-52. [PubMed 15770831]
  6. Montgomery LA, Hanrahan K, Kottman K, et al, “Guideline for I.V. Infiltrations in Pediatric Patients,” Pediatr Nurs, 1999, 25(2):167-9, 173-80. [PubMed 10532013]
  7. Mouridsen HT, Langer SW, Buter J, et al, “Treatment of Anthracycline Extravasation With Savene (Dexrazoxane): Results From Two Prospective Clinical Multicentre Studies,” Ann Oncol, 2007, 18(3):546-50. [PubMed 17185744]
  8. Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” Ann Oncol, 2012, 23(Suppl 7):167-73. [PubMed 22997449]
  9. Rimso-50 (dimethyl sulfoxide) [prescribing information]. Rockford, IL: Mylan Institutional LLC; July 2012.
  10. Rimso-50 (dimethyl sulfoxide) [prescribing information]. Rockford, IL: Mylan Institutional; April 2018.
  11. Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs. 2011;27(1):82-90. [PubMed 21255716]
Topic 8898 Version 131.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟